From delocalized lipophilic cations to hypoxia: blocking tumor cell mitochondrial function leads to therapeutic gain with glycolytic inhibitors.

PubWeight™: 0.99‹?› | Rank: Top 15%

🔗 View Article (PMC 2928140)

Published in Mol Nutr Food Res on January 01, 2009

Authors

Metin Kurtoglu1, Theodore J Lampidis

Author Affiliations

1: Miller School of Medicine, University of Miami, Miami, FL 33136, USA.

Articles citing this

Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. Cancer Res (2012) 1.49

Methods for detection of mitochondrial and cellular reactive oxygen species. Antioxid Redox Signal (2012) 1.20

Mitochondria-targeted vitamin E analogs inhibit breast cancer cell energy metabolism and promote cell death. BMC Cancer (2013) 1.04

Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation. Br J Cancer (2014) 0.97

Mitochondrial bioenergetic profile and responses to metabolic inhibition in human hepatocarcinoma cell lines with distinct differentiation characteristics. J Bioenerg Biomembr (2011) 0.87

Antiproliferative effects of mitochondria-targeted cationic antioxidants and analogs: Role of mitochondrial bioenergetics and energy-sensing mechanism. Cancer Lett (2015) 0.86

Mitochondria-targeted nitroxides exacerbate fluvastatin-mediated cytostatic and cytotoxic effects in breast cancer cells. Cancer Biol Ther (2011) 0.84

Dual-targeting of aberrant glucose metabolism in glioblastoma. J Exp Clin Cancer Res (2015) 0.82

Targeting of mitochondria-endoplasmic reticulum by fluorescent macrocyclic compounds. PLoS One (2011) 0.80

Tunable cytotoxicity of rhodamine 6G via anion variations. J Am Chem Soc (2013) 0.79

Mitochondria-targeted antioxidant and glycolysis inhibition: synergistic therapy in hepatocellular carcinoma. Anticancer Drugs (2013) 0.79

Rosamines targeting the cancer oxidative phosphorylation pathway. PLoS One (2014) 0.76

Preparation and Evaluation of a Novel Class of Amphiphilic Amines as Antitumor Agents and Nanocarriers for Bioactive Molecules. Pharm Res (2016) 0.75

Cytochrome c modulates the mitochondrial signaling pathway and polymorphonuclear neutrophil apoptosis in bile duct-ligated rats. Exp Ther Med (2016) 0.75

A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: Therapeutic targeting of tumor mitochondria with lipophilic cationic compounds. Redox Biol (2017) 0.75

Articles cited by this

A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet (2005) 16.79

Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res (1989) 12.85

Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem (1994) 9.21

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta (1976) 7.41

Localization of mitochondria in living cells with rhodamine 123. Proc Natl Acad Sci U S A (1980) 7.31

Aromatic-aromatic interaction: a mechanism of protein structure stabilization. Science (1985) 6.87

General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A (1993) 6.77

Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A (1987) 5.65

Mitochondrial membrane potential in living cells. Annu Rev Cell Biol (1988) 4.73

Monitoring of relative mitochondrial membrane potential in living cells by fluorescence microscopy. J Cell Biol (1981) 3.97

Weakly polar interactions in proteins. Adv Protein Chem (1988) 3.26

Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta (1973) 2.88

Activation of the HIF pathway in cancer. Curr Opin Genet Dev (2001) 2.38

The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol (1989) 2.35

Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of rhodamine 123 by human breast adenocarcinoma-derived MCF-7 cells. J Biol Chem (1985) 2.18

Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas. Int J Radiat Oncol Biol Phys (1996) 2.15

Multidrug resistance of DNA-mediated transformants is linked to transfer of the human mdr1 gene. Mol Cell Biol (1986) 1.89

Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol (2003) 1.78

Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv Drug Deliv Rev (2001) 1.77

Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol (1988) 1.72

Unusual retention of rhodamine 123 by mitochondria in muscle and carcinoma cells. Proc Natl Acad Sci U S A (1982) 1.72

Ionophores. Methods Enzymol (1979) 1.62

A single membrane-embedded negative charge is critical for recognizing positively charged drugs by the Escherichia coli multidrug resistance protein MdfA. EMBO J (1999) 1.61

Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res (2000) 1.55

Regulation of hypoxia-inducible factor is preserved in the absence of a functioning mitochondrial respiratory chain. Blood (2001) 1.54

Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry (2001) 1.52

Probing mitochondria in living cells with rhodamine 123. Cold Spring Harb Symp Quant Biol (1982) 1.46

Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc Natl Acad Sci U S A (1989) 1.34

Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. Mol Cancer Ther (2007) 1.22

Selective killing of carcinoma cells "in vitro" by lipophilic-cationic compounds: a cellular basis. Biomed Pharmacother (1985) 1.19

Selective toxicity of rhodamine 123 in carcinoma cells in vitro. Cancer Res (1983) 1.19

Cardiac toxicity of daunorubicin. Lancet (1969) 1.18

Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye. Science (1983) 1.17

Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). Biochem Pharmacol (2002) 1.15

Mitochondrial biogenesis in the liver during development and oncogenesis. J Bioenerg Biomembr (1997) 1.14

Targeting hypoxia, a novel treatment for advanced retinoblastoma. Invest Ophthalmol Vis Sci (2008) 1.12

Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge. Biochemistry (1997) 1.10

Transmembrane aromatic amino acid distribution in P-glycoprotein. A functional role in broad substrate specificity. J Mol Biol (1994) 1.00

Increased steady-state levels of several mitochondrial and nuclear gene transcripts in rat hepatoma with a low content of mitochondria. Eur J Biochem (1992) 0.99

Cellular resistance to daunomycin in Chinese hamster cells in vitro. Cancer Res (1971) 0.99

Decreased uptake and retention of rhodamine 123 by mitochondria in feline sarcoma virus-transformed mink cells. Cell (1982) 0.97

Oxidative phosphorylation enzymes in normal and neoplastic cell growth. J Bioenerg Biomembr (1997) 0.95

Structural and functional effects of adriamycin on cardiac cells in vitro. Cancer Res (1980) 0.94

A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077. Clin Cancer Res (2000) 0.93

Mitochondrial alterations in human gastric carcinoma cell line. Am J Physiol Cell Physiol (2007) 0.92

Expression of mitochondrial cytochrome c oxidase in human colonic cell differentiation, transformation, and risk for colonic cancer. Cancer Res (1990) 0.92

Rhodamine 123 inhibits bioenergetic function in isolated rat liver mitochondria. Biochem Biophys Res Commun (1984) 0.91

Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity. Anticancer Drugs (1993) 0.89

Structural requirements of simple organic cations for recognition by multidrug-resistant cells. Cancer Res (1992) 0.88

Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double-advantage approach. Pharmacol Ther (1993) 0.88

Relationship of multidrug resistance to rhodamine-123 selectivity between carcinoma and normal epithelial cells: taxol and vinblastine modulate drug efflux. Cancer Res (1995) 0.87

Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat Rep (1978) 0.86

A study of some mitochondrial and peroxisomal enzymes in human colonic adenocarcinoma. Lab Invest (1981) 0.85

Interaction of rhodamine 123 with mitochondria isolated from drug-sensitive and -resistant Friend leukemia cells. Biochem Biophys Res Commun (1985) 0.85

Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties. Cancer Res (1994) 0.85

Reduced ouabain-sensitive potassium entry as a possible mechanism of multidrug-resistance in P388 cells. Biochem Pharmacol (1991) 0.83

Function of the anthracycline amino group in cellular transport and cytotoxicity. Mol Pharmacol (1987) 0.82

Rational design and pre-clinical pharmacology of drugs for reversing multidrug resistance. Biochem Pharmacol (1992) 0.82

Structure-activity relationships of antineoplastic agents in multidrug resistance. J Med Chem (1990) 0.80

Effects of adriamycin on rat heart cells in culture: increased accumulation and nucleoli fragmentation in cardiac muscle v. non-muscle cells. J Mol Cell Cardiol (1981) 0.79

Comparison of the adenine nucleotide translocase in hepatomas and rat liver mitochondria. Biochim Biophys Acta (1979) 0.77

Resistance to lipophilic cationic compounds in multidrug resistant leukemia cells. Leuk Lymphoma (1993) 0.77

Effects of the mitochondrial probe rhodamine 123 and related analogs on the function and viability of pulsating myocardial cells in culture. Agents Actions (1984) 0.77

Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells. Pathol Biol (Paris) (1994) 0.76

Relationship between the structure of analogues of amsacrine and their degree of cross-resistance to adriamycin-resistant P388 leukaemia cells. Eur J Cancer Clin Oncol (1988) 0.76

Preclinical toxicity of liposome-incorporated annamycin: selective bone marrow toxicity with lack of cardiotoxicity. Clin Cancer Res (1995) 0.76

Ursodeoxycholate promotes protein phosphorylation in the cytosol of rat hepatocytes. Biochem Mol Biol Int (1997) 0.76

Articles by these authors

2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res (2004) 2.88

Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol (2003) 1.78

Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol Cancer Ther (2007) 1.54

A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol (2012) 1.41

2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion. Cancer Chemother Pharmacol (2010) 1.35

Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells. Antioxid Redox Signal (2007) 1.26

Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. Mol Cancer Ther (2007) 1.22

Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). Biochem Pharmacol (2002) 1.15

Targeting hypoxia, a novel treatment for advanced retinoblastoma. Invest Ophthalmol Vis Sci (2008) 1.12

Antiangiogenic activity of 2-deoxy-D-glucose. PLoS One (2010) 1.08

Differential sensitivity to 2-deoxy-D-glucose between two pancreatic cell lines correlates with GLUT-1 expression. Pancreas (2005) 1.08

Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines. Mol Cancer Ther (2008) 0.96

Multidrug resistance correlates with overexpression of Muc4 but inversely with P-glycoprotein and multidrug resistance related protein in transfected human melanoma cells. Biochem Pharmacol (2003) 0.95

Inhibition of Akt potentiates 2-DG-induced apoptosis via downregulation of UPR in acute lymphoblastic leukemia. Mol Cancer Res (2012) 0.95

Increased hypoxia following vessel targeting in a murine model of retinoblastoma. Invest Ophthalmol Vis Sci (2009) 0.95

Endoplasmic reticulum stress induced by 2-deoxyglucose but not glucose starvation activates AMPK through CaMKKβ leading to autophagy. Biochem Pharmacol (2013) 0.94

The wonders of 2-deoxy-D-glucose. IUBMB Life (2014) 0.94

Activation of the unfolded protein response by 2-deoxy-D-glucose inhibits Kaposi's sarcoma-associated herpesvirus replication and gene expression. Antimicrob Agents Chemother (2012) 0.86

The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells. Mol Cancer Ther (2012) 0.85

Focal, periocular delivery of 2-deoxy-D-glucose as adjuvant to chemotherapy for treatment of advanced retinoblastoma. Invest Ophthalmol Vis Sci (2010) 0.84

Models and discovery strategies for new therapies of retinoblastoma. Expert Opin Drug Discov (2013) 0.83

High endoplasmic reticulum activity renders multiple myeloma cells hypersensitive to mitochondrial inhibitors. Cancer Chemother Pharmacol (2009) 0.81

Conversion of 2-deoxyglucose-induced growth inhibition to cell death in normoxic tumor cells. Cancer Chemother Pharmacol (2013) 0.81

Targeting cisplatin-resistant human tumor cells with metabolic inhibitors. Cancer Chemother Pharmacol (2013) 0.79

Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-D-glucose. Cancer Chemother Pharmacol (2013) 0.76

Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LH(BETA)T(AG) retinal tumors. Clin Ophthalmol (2012) 0.75